Interstitial photodynamic therapy of nonresectable malignant glioma recurrences using 5-aminolevulinic acid induced protoporphyrin IX

2007 ◽  
Vol 39 (5) ◽  
pp. 386-393 ◽  
Author(s):  
Tobias J. Beck ◽  
Friedrich W. Kreth ◽  
Wolfgang Beyer ◽  
Jan H. Mehrkens ◽  
Andreas Obermeier ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
Malignant Glioma ◽  
Aminolevulinic Acid ◽  
Protoporphyrin Ix ◽  
Interstitial Photodynamic Therapy

Protoporphyrin IX kinetics for interstitial photodynamic therapy dosimetry of malignant glioma

2011 ◽  
Vol 8 (2) ◽  
pp. 210-211
Author(s):  
W. Beyer ◽  
A. Johansson ◽  
F. Faber ◽  
G. Palte ◽  
H. Stepp ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
Malignant Glioma ◽  
Protoporphyrin Ix ◽  
Interstitial Photodynamic Therapy

scholarly journals Interstitial Photodynamic Therapy Using 5-ALA for Malignant Glioma Recurrences

Cancers ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 1767
Author(s):  
Stefanie Lietke ◽  
Michael Schmutzer ◽  
Christoph Schwartz ◽  
Jonathan Weller ◽  
Sebastian Siller ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
Prognostic Factors ◽  
Malignant Glioma ◽  
Treatment Response ◽  
Aminolevulinic Acid ◽  
Malignant Gliomas ◽  
Target Volume ◽  
Risk Profile ◽  
Who Grade ◽  
Interstitial Photodynamic Therapy

Interstitial photodynamic therapy (iPDT) using 5-aminolevulinic acid (5-ALA)-induced protoporphyrin IX (PpIX) as a cytotoxic photosensitizer could be a feasible treatment option for malignant gliomas. In a monocentric cohort of consecutive patients treated between 2006 and 2018, a risk profile analysis of salvage iPDT for local malignant glioma recurrences and associated outcome measures are presented here. It was considered indicated in patients with circumscribed biopsy-proven malignant glioma recurrences after standard therapy, if not deemed eligible for safe complete resection. A 3D treatment-planning software was used to determine the number and suitable positions of the cylindrical diffusing fibers placed stereotactically to ensure optimal interstitial irradiation of the target volume. Outcome measurements included the risk profile of the procedure, estimated time-to-treatment-failure (TTF), post-recurrence survival (PRS) and prognostic factors. Forty-seven patients were treated, of which 44 (median age, 49.4 years, range, 33.4–87.0 years, 27 males) could be retrospectively evaluated. Recurrent gliomas included 37 glioblastomas (WHO grade IV) and 7 anaplastic astrocytomas (WHO grade III). Thirty (68.2%) tumors were O-6-methylguanine-DNA methyltransferase (MGMT)-methylated, 29 (65.9%)—isocitrate dehydrogenase (IDH)-wildtype. Twenty-six (59.1%) patients were treated for their first, 9 (20.5%)—for their second, 9 (20.5%)—for the third or further recurrence. The median iPDT target volume was 3.34 cm3 (range, 0.50–22.8 cm3). Severe neurologic deterioration lasted for more than six weeks in one patient only. The median TTF was 7.1 (95% confidence interval (CI), 4.4–9.8) months and the median PRS was 13.0 (95% CI, 9.2–16.8) months. The 2- and 5-year PRS rates were 25.0% and 4.5%, respectively. The treatment response was heterogeneous and not significantly associated with patient characteristics, treatment-related factors or molecular markers. The promising outcome and acceptable risk profile deserve further prospective evaluation particularly to identify mechanisms and prognostic factors of favorable treatment response.

Protoporphyrin IX Fluorescence Photobleaching and the Response of Rat Barrett's Esophagus Following 5-aminolevulinic Acid Photodynamic Therapy

2006 ◽  
Vol 82 (6) ◽  
pp. 1638 ◽  
Author(s):  
Ingrid A. Boere ◽  
Dominic J. Robinson ◽  
Henriette S. de Bruijn ◽  
Jolanda Kluin ◽  
Hugo W. Tilanus ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
Barrett’S Esophagus ◽  
Barrett's Esophagus ◽  
Aminolevulinic Acid ◽  
Protoporphyrin Ix

scholarly journals Systematic Review and Meta-Analysis of In Vitro Anti-Human Cancer Experiments Investigating the Use of 5-Aminolevulinic Acid (5-ALA) for Photodynamic Therapy

2021 ◽  
Vol 14 (3) ◽  
pp. 229
Author(s):  
Yo Shinoda ◽  
Daitetsu Kato ◽  
Ryosuke Ando ◽  
Hikaru Endo ◽  
Tsutomu Takahashi ◽  
...  
Keyword(s):  
Systematic Review ◽  
Photodynamic Therapy ◽  
Aminolevulinic Acid ◽  
Human Cancer ◽  
Meta Analysis ◽  
Protoporphyrin Ix ◽  
Cell Types ◽  
Amino Acid Derivative ◽  
Photodynamic Diagnosis

5-Aminolevulinic acid (5-ALA) is an amino acid derivative and a precursor of protoporphyrin IX (PpIX). The photophysical feature of PpIX is clinically used in photodynamic diagnosis (PDD) and photodynamic therapy (PDT). These clinical applications are potentially based on in vitro cell culture experiments. Thus, conducting a systematic review and meta-analysis of in vitro 5-ALA PDT experiments is meaningful and may provide opportunities to consider future perspectives in this field. We conducted a systematic literature search in PubMed to summarize the in vitro 5-ALA PDT experiments and calculated the effectiveness of 5-ALA PDT for several cancer cell types. In total, 412 articles were identified, and 77 were extracted based on our inclusion criteria. The calculated effectiveness of 5-ALA PDT was statistically analyzed, which revealed a tendency of cancer-classification-dependent sensitivity to 5-ALA PDT, and stomach cancer was significantly more sensitive to 5-ALA PDT compared with cancers of different origins. Based on our analysis, we suggest a standardized in vitro experimental protocol for 5-ALA PDT.

scholarly journals eEF1A1 binds and enriches protoporphyrin IX in cancer cells in 5-aminolevulinic acid based photodynamic therapy

2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Zhichao Fan ◽  
Xiaojun Cui ◽  
Dan Wei ◽  
Wei Liu ◽  
Buhong Li ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
Cancer Cells ◽  
Aminolevulinic Acid ◽  
Protoporphyrin Ix

scholarly journals Fluorescence-Guided Resection of Malignant Glioma with 5-ALA

2016 ◽  
Vol 2016 ◽  
pp. 1-11 ◽  
Author(s):  
Sadahiro Kaneko ◽  
Sadao Kaneko
Keyword(s):  
Malignant Glioma ◽  
Anticancer Agents ◽  
Aminolevulinic Acid ◽  
Malignant Gliomas ◽  
Protoporphyrin Ix ◽  
Time Spectrum ◽  
Photodynamic Diagnosis ◽  
Promising Technique ◽  
New Methods ◽  
New Treatments

Malignant gliomas are extremely difficult to treat with no specific curative treatment. On the other hand, photodynamic medicine represents a promising technique for neurosurgeons in the treatment of malignant glioma. The resection rate of malignant glioma has increased from 40% to 80% owing to 5-aminolevulinic acid-photodynamic diagnosis (ALA-PDD). Furthermore, ALA is very useful because it has no serious complications. Based on previous research, it is apparent that protoporphyrin IX (PpIX) accumulates abundantly in malignant glioma tissues after ALA administration. Moreover, it is evident that the mechanism underlying PpIX accumulation in malignant glioma tissues involves an abnormality in porphyrin-heme metabolism, specifically decreased ferrochelatase enzyme activity. During resection surgery, the macroscopic fluorescence of PpIX to the naked eye is more sensitive than magnetic resonance imaging, and the alert real time spectrum of PpIX is the most sensitive method. In the future, chemotherapy with new anticancer agents, immunotherapy, and new methods of radiotherapy and gene therapy will be developed; however, ALA will play a key role in malignant glioma treatment before the development of these new treatments. In this paper, we provide an overview and present the results of our clinical research on ALA-PDD.

Sign in / Sign up

Export Citation Format

Share Document